Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$9.94 -1.0%	$5.39	$3.35 ▼ $20.55	$278.72M	1.04	208,676 shs	214,010 shs
STOK Stoke Therapeutics	$19.56 -0.6%	$13.31	$5.35 ▼ $19.91	$1.07B	1.15	888,701 shs	1.15 million shs
VALN Valneva	$11.64 +4.0%	$7.41	$3.62 ▼ $12.25	$990.45M	1.77	87,673 shs	48,007 shs
ZYME Zymeworks	$15.10 +4.9%	$13.22	$9.03 ▼ $17.70	$1.14B	1.26	530,202 shs	481,670 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	0.00%	+34.69%	+72.27%	+178.43%	-50.45%
STOK Stoke Therapeutics	0.00%	+7.41%	+49.31%	+108.97%	+39.81%
VALN Valneva	0.00%	+0.95%	+51.56%	+88.35%	+50.00%
ZYME Zymeworks	0.00%	+5.15%	+13.28%	+30.85%	+32.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.3219 of 5 stars	3.6	5.0	0.0	3.1	0.8	0.6
STOK Stoke Therapeutics	4.5611 of 5 stars	4.6	1.0	4.8	2.6	0.8	1.3
VALN Valneva	2.1938 of 5 stars	3.5	3.0	0.0	2.6	0.8	0.0
ZYME Zymeworks	1.7864 of 5 stars	3.5	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.75	128.87% Upside
STOK Stoke Therapeutics	3.22	Buy	$25.57	30.73% Upside
VALN Valneva	3.00	Buy	$16.00	37.46% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	41.91% Upside

Current Analyst Ratings Breakdown

Latest CTNM, ZYME, STOK, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	VALN Valneva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
8/18/2025	STOK Stoke Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$28.00
8/18/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	5.57	N/A	N/A	$7.66 per share	1.30
STOK Stoke Therapeutics	$36.56M	29.32	N/A	N/A	$4.32 per share	4.53
VALN Valneva	$183.52M	5.40	$0.10 per share	119.13	$2.41 per share	4.83
ZYME Zymeworks	$122.87M	9.24	N/A	N/A	$6.63 per share	2.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.85	23.01	N/A	N/A	26.25%	18.32%	15.48%	11/4/2025 (Estimated)
VALN Valneva	-$13.25M	-$0.98	N/A	N/A	N/A	-33.87%	-34.78%	-13.43%	11/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest CTNM, ZYME, STOK, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	$54.84 million
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	24.51	24.51
STOK Stoke Therapeutics	N/A	6.98	6.98
VALN Valneva	0.66	2.27	1.77
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
STOK Stoke Therapeutics	N/A
VALN Valneva	11.39%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
STOK Stoke Therapeutics	9.50%
VALN Valneva	14.91%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A
STOK Stoke Therapeutics	100	54.80 million	49.59 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

CTNM, ZYME, STOK, and VALN Headlines

Recent News About These Companies

Zymeworks Reports Q2 Results and FDA Clearance

August 19, 2025 | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13, 2025 | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12, 2025 | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | marketbeat.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11, 2025 | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11, 2025 | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11, 2025 | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and ...

July 30, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, ZYME, STOK, and VALN Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$9.94 -0.10 (-1.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.46 -0.48 (-4.83%)

As of 08/22/2025 07:59 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Stoke Therapeutics NASDAQ:STOK

$19.56 -0.12 (-0.61%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.86 +0.30 (+1.51%)

As of 04:05 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Valneva NASDAQ:VALN

$11.64 +0.45 (+4.02%)

As of 08/22/2025 02:47 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Zymeworks NYSE:ZYME

$15.10 +0.71 (+4.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.11 +0.01 (+0.07%)

As of 04:59 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time